拉贝洛尔（柳胺苄心定）、普萘洛尔与安慰剂治疗轻至中度高血压的对照试验
A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension.
作者信息
Pugsley D J, Nassim M, Armstrong B K, Beilin L
出版信息
Br J Clin Pharmacol. 1979 Jan;7(1):63-8. doi: 10.1111/j.1365-2125.1979.tb00898.x.
Abstract
- Labetalol, a new drug combining alpha-and beta-adrenoceptor blocking properties, has been compared with placebo in a double-blind crossover study of a group of patients with mild to moderate essential hypertension (blood pressure 150/100 to 189/114 mmHg). 2. Labetalol and propranolol lowered blood pressure satisfactorily in the supine position, but labetalol reduced blood pressure more in the erect posture and following exercise and induced less bradycardia. Thus alpha- as well as beta-adrenoceptor blocking actions appear to contribute to blood pressure reduction. 3. Side effects attributable to labetalol were few. The effective dose ratio labetalol: propranolol was 2.5:1 (w/w). 4. Labetalol, a new form of hypotensive agent, merits further controlled assessment of its usefulness in relation to existing drugs.
摘要
- 拉贝洛尔是一种兼具α和β肾上腺素受体阻断特性的新药，在一组轻度至中度原发性高血压患者（血压为150/100至189/114 mmHg）的双盲交叉研究中，已将其与安慰剂进行了比较。2. 拉贝洛尔和普萘洛尔在仰卧位时能令人满意地降低血压，但拉贝洛尔在直立姿势和运动后能更大程度地降低血压，且引起的心动过缓较少。因此，α以及β肾上腺素受体阻断作用似乎都有助于降低血压。3. 归因于拉贝洛尔的副作用很少。拉贝洛尔与普萘洛尔的有效剂量比为2.5:1（重量/重量）。4. 拉贝洛尔作为一种新型降压药，值得就其与现有药物相比的有效性进行进一步的对照评估。
相似文献
1
A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension.拉贝洛尔（柳胺苄心定）、普萘洛尔与安慰剂治疗轻至中度高血压的对照试验
Br J Clin Pharmacol. 1979 Jan;7(1):63-8. doi: 10.1111/j.1365-2125.1979.tb00898.x.
2
Controlled comparison of labetalol and propranolol in the management of severe hypertension.拉贝洛尔与普萘洛尔治疗重度高血压的对照比较。
Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):777-82.
3
Comparison of labetalol, hydrallazine, and propranolol in the therapy of moderate hypertension.拉贝洛尔、肼屈嗪和普萘洛尔治疗中度高血压的比较。
Med J Aust. 1980 Mar 8;1(5):224-5.
4
Comparison of labetalol and propranolol in hypertension.拉贝洛尔与普萘洛尔治疗高血压的比较。
Br J Clin Pharmacol. 1980 Mar;9(3):233-7. doi: 10.1111/j.1365-2125.1980.tb04832.x.
5
Combined alpha- and beta-adrenoreceptor blockade in hypertension: a controlled trial of labetalol (AH 5158) compared with propranolol and placebo.α和β肾上腺素能受体联合阻滞治疗高血压：拉贝洛尔（AH 5158）与普萘洛尔及安慰剂对比的对照试验
Clin Sci Mol Med Suppl. 1976 Dec;3:501s-503s. doi: 10.1042/cs051501s.
6
A double-blind crossover clinical trial of labetalol and propranolol in patients of essential hypertension.拉贝洛尔与普萘洛尔治疗原发性高血压患者的双盲交叉临床试验。
Int J Clin Pharmacol Ther Toxicol. 1985 Feb;23(2):101-4.
7
Labetalol compared with propranolol in patients with both angina pectoris and systemic hypertension: a double-blind study.拉贝洛尔与普萘洛尔治疗心绞痛合并系统性高血压患者的疗效比较：一项双盲研究。
J Clin Pharmacol. 1989 Jun;29(6):504-11. doi: 10.1002/j.1552-4604.1989.tb03372.x.
8
Antihypertensive effect and plasma levels of labetalol. A comparison with propranolol and dihydrallazine.拉贝洛尔的降压作用及血浆水平。与普萘洛尔和双肼屈嗪的比较。
Int J Clin Pharmacol Biopharm. 1979 Feb;17(2):71-5.
9
Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension.拉贝洛尔与美托洛尔治疗轻至中度系统性高血压的多诊所比较。
Am J Med. 1983 Oct 17;75(4A):54-67. doi: 10.1016/0002-9343(83)90137-7.
10
Labetalol in the treatment of hypertension in patients with normal and impaired renal function.拉贝洛尔治疗肾功能正常和受损患者的高血压
Acta Med Scand Suppl. 1982;665:135-41. doi: 10.1111/j.0954-6820.1982.tb00423.x.
引用本文的文献
1
Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension.原发性高血压患者使用拉贝洛尔治疗期间的血压、体液容量及肾小球滤过率
Br J Clin Pharmacol. 1981 Sep;12(3):349-53. doi: 10.1111/j.1365-2125.1981.tb01225.x.
2
Comparison of labetalol, propranolol and hydralazine in hypertensive out-patients.拉贝洛尔、普萘洛尔和肼屈嗪在高血压门诊患者中的比较。
Eur J Clin Pharmacol. 1982;21(6):457-60. doi: 10.1007/BF00542038.
3
Comparison of labetalol and propranolol in hypertension.拉贝洛尔与普萘洛尔治疗高血压的比较。
Br J Clin Pharmacol. 1980 Mar;9(3):233-7. doi: 10.1111/j.1365-2125.1980.tb04832.x.
4
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.联合α和β受体抑制治疗高血压。
Drugs. 1984;28 Suppl 2:51-68. doi: 10.2165/00003495-198400282-00005.
5
Comparison of labetalol with other anti-hypertensive drugs.拉贝洛尔与其他抗高血压药物的比较。
Br J Clin Pharmacol. 1982 Jun;13(1 Suppl):41S-47S. doi: 10.1111/j.1365-2125.1982.tb01888.x.
6
A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension.拉贝洛尔与哌唑嗪联合阿替洛尔治疗阿替洛尔加氢氯噻嗪治疗无效的单纯性高血压患者的比较
Eur J Clin Pharmacol. 1985;28(5):507-11. doi: 10.1007/BF00544059.
7
Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.拉贝洛尔（一种兼具α和β受体阻滞作用的药物）与心肌缺血治疗相关的特性。
Cardiovasc Drugs Ther. 1988 Sep;2(3):343-53. doi: 10.1007/BF00054642.
本文引用的文献
1
Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.AH 5158的药理学；一种能阻断α和β肾上腺素能受体的药物。
Br J Pharmacol. 1972 Aug;45(4):660-75. doi: 10.1111/j.1476-5381.1972.tb08125.x.
2
Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.α和β肾上腺素能受体拮抗剂AH5158A的临床研究
Br J Pharmacol. 1972 Feb;44(2):286-93. doi: 10.1111/j.1476-5381.1972.tb07265.x.
3
Alpha and beta adrenergic blockade in hypertension.高血压中的α和β肾上腺素能阻滞剂
Lancet. 1972 May 6;1(7758):979-82. doi: 10.1016/s0140-6736(72)91154-3.
4
Labetalol in resistant hypertension.拉贝洛尔用于顽固性高血压
Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):751-5.
5
Efficacy of antihypertensive drugs.抗高血压药物的疗效。
Lancet. 1976 Mar 6;1(7958):515-8. doi: 10.1016/s0140-6736(76)90299-3.
6
A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.拉贝洛尔（一种α和β肾上腺素受体阻断联合药物）的动物药理学综述。
Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):681-4.
7
Diseases of the cardiovascular system Hypertension--II.心血管系统疾病——高血压——II。
Br Med J. 1976 Aug 7;2(6031):359-61. doi: 10.1136/bmj.2.6031.359.
Zotero 插件